Free tool
FAERS Monitor: Omnaris
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022004 or its brand name (Omnaris, Ciclesonide). Reports on generic versions are filed under their own applications.
Reports
4,999
Serious
4,577
92% of reports
Hospitalization
2,249
Death reported
264
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthma1,876
- dyspnoea1,500
- wheezing1,439
- therapeutic product effect incomplete1,057
- obstructive airways disorder851
- productive cough759
- cough740
- condition aggravated682
- pneumonia654
- full blood count abnormal614
- drug ineffective596
- sleep disorder due to a general medical condition588
- loss of personal independence in daily activities533
- off label use474
- chest discomfort467
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 11 |
| 2009 | 43 |
| 2010 | 74 |
| 2011 | 68 |
| 2012 | 112 |
| 2013 | 88 |
| 2014 | 99 |
| 2015 | 157 |
| 2016 | 237 |
| 2017 | 186 |
| 2018 | 220 |
| 2019 | 435 |
| 2020 | 609 |
| 2021 | 728 |
| 2022 | 459 |
| 2023 | 355 |
| 2024 | 426 |
| 2025 | 391 |
| 2026 | 296 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,160 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| obstructive airways disorderSignal | 851 | 348.5 | 326.9 | 272,182 |
| full blood count abnormalSignal | 614 | 259.2 | 240.1 | 148,588 |
| sleep disorder due to a general medical conditionSignal | 588 | 150.9 | 139.6 | 84,428 |
| wheezingSignal | 1,439 | 104.6 | 100.1 | 144,392 |
| asthmaSignal | 1,876 | 71.0 | 68.5 | 127,948 |
| productive coughSignal | 759 | 68.0 | 63.6 | 49,329 |
| therapeutic product effect incompleteSignal | 1,057 | 63.4 | 60.1 | 64,154 |
| loss of personal independence in daily activitiesSignal | 533 | 47.2 | 43.5 | 23,844 |
| chest discomfortSignal | 467 | 19.3 | 17.7 | 8,074 |
| dyspnoeaSignal | 1,500 | 11.2 | 10.7 | 14,234 |
| coughSignal | 740 | 11.1 | 10.4 | 6,886 |
| condition aggravatedSignal | 682 | 9.5 | 8.8 | 5,213 |
| pneumoniaSignal | 654 | 8.5 | 7.9 | 4,388 |
| off label useSignal | 474 | 2.3 | 2.1 | 353 |
| drug ineffective | 596 | 1.9 | 1.8 | 271 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.